Global Uterine Fibroid Treatment Devices Market Report and Forecast 2024-2032

Global Uterine Fibroid Treatment Devices Market Outlook

The global uterine fibroid treatment devices market size attained a value of USD 6.53 billion in 2023. The market is further anticipated to grow at a CAGR of 9.5% during the forecast period of 2024-2032 to attain a value of USD 14.77 billion by 2032.  

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Company News

In July 2023, Linzagolix, which has been a promising contender for treating uterine fibroids for a long time, was discontinued, according to the Swiss women's health business ObsEva. In order to better support its current license agreements, the company will also go through a corporate restructuring process and review its development and commercialisation strategy.

In August 2023, Myovant & Pfizer's Myfembree received the USFDA approval for the treatment of moderate to severe pain brought on by uterine fibroids.

Uterine Fibroid Treatment Devices Market Insights

Fibroids are muscular tumours that get developed in the uterine wall (womb). Fibroids are benign and are usually not cancerous. The symptoms can differ from woman to woman. While some patients experience extreme symptoms like excessive menstrual bleeding, along with painful cramps, there are patients who do not experience any major symptoms.

Based on these symptoms, the treatment procedure for uterine fibroids is determined.

In the uterus, fibroids can develop into a single or multiple tumour. They can range in size from a grapefruit to an apple seed and have a rare capacity to grow extremely huge. The development of uterine fibroid increases in women in the age group of 30-40 and the fibroid sizes change post-menopause.

Genetic history also plays a vital role in the development of fibroids in a woman, and risk of developing fibroids is almost three times higher than average, if the patient’s mother had it.

Factors like weight and lifestyle also act as causative factors in the development of uterine fibroids as overweight women are more likely to have fibroids. The risk is two to three times higher than average for very overweight women and consumption of a lot of ham and red meat, such as beef, is associated with an increased chance of developing fibroids. Consuming a lot of green vegetables appears to shield females from getting fibroids.

Based on the location of the fibroids it is segmented into Submucosal (inside the uterine cavity), Intramural (within the wall of the uterus), Subserosal (outside the uterus), and some fibroids look like mushrooms, known as pedunculated fibroids. These mushroom like fibroids grow out from the surface or into the cavity of the uterus.

Fibroids do not cause any symptoms but sometimes can lead to heavy/painful bleeding, heaviness in the pelvic region, enlargement of the lower abdomen, frequent urination, painful intercourse, lower back, and leg pain, among others.

Fibroids with mild symptoms are usually treated with over-the-counter medication like ibuprofen or acetaminophen, and iron supplements for anemic patients. Several hormonal replacement therapies like birth control pills or progesterone injections are induced to control the symptoms of uterine fibroid. And other drugs like gonadotrophin-releasing hormone agonists through a different route of administration are also used for the treatment.

Fibroids with moderate to severe symptoms are treated with the following surgeries:

Myomectomy: Helps remove fibroids without removing the healthy tissues in the uterus. It is the best alternative for women who want to keep their uterus intact or who want to become pregnant following fibroids therapy. There are numerous ways to do a myomectomy. Major abdominal surgery or procedures utilising laparoscopy or hysteroscopy can be used to treat it. The kind, size, and location of the fibroids determine the kind of surgery that can be performed.

Hysterectomy: In this procedure, the uterus is surgically removed. The only effective treatment for uterine fibroids is this procedure. Hysterectomy carries a high risk of complications even though the procedure is often relatively safe.

Endometrial ablation: To stop extremely severe bleeding, the uterine lining is either removed or damaged. This can be accomplished using a laser, wire loops, microwaves, electric currents, boiling water, and other techniques.

Myolysis: A laparoscopy is utilised to guide the insertion of the needle into the fibroids and are then destroyed using an electric current or by freezing them.

Uterine Fibroid Embolization/ Uterine Artery Embolization: To supply blood to the fibroids a thin tube is threaded to the blood vessels, leading it to shrink. This procedure is best for women with heavy bleeding, pressed bladder, who do not intend to conceive in the future.

Uterine Fibroid Treatment Devices Market Overview

The uterine fibroid treatment devices market is further segmented into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Mode of Treatment

• Invasive System

• Non-Invasive System

• Minimally Invasive System

Market Breakup by Techniques

• Surgical Techniques

• Hysterectomy

• Myomectomy

• Laparoscopic Techniques

• Laparoscopic

• Myolosis

• Ablation Techniques

• Microwave Ablation

• Cryoablation

• Ultrasound Ablation

• Embolization Techniques

• Others

Market Breakup by Disease Type

• Uterine Leiomyoma (Fibroids)

• Others

Market Breakup by End-User

• Hospitals

• Dialysis Centres

• Others

Market Breakup by Region

• North America

• Europe 

• Asia Pacific 

• Latin America 

• Middle East and Africa 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Uterine Fibroid Treatment Devices Market Trends

In women of reproductive age, the uterine fibroid is a typical cause of various bleeding and pain symptoms that can negatively affect a variety of aspects of a woman's life.

The primary factors anticipated to propel the market are the high prevalence of uterine fibroids, along with the increased patient preference for minimally invasive procedures. The adoption of sophisticated technologies is also bolstering the growth of the uterine fibroid treatment devices market. The benign tumour of smooth muscle cells, called a uterine fibroid (UF), develops in a woman's uterus and can cause excessive menstrual flow, pelvic pain, infertility, and frequent urination.

The risk factors include race, age, familial predisposition, premenopausal status, hypertension, overweight, and diet, even though their etiology is still unknown. Asymptomatic uterine fibroid patients, which account for 50 to 75 percent of cases, receive less clinical attention and frequently go undetected.

Fibroid operations that need little to no incision are anticipated to boost the market expansion. Smaller incisions reduce post-operative pain and speed up recovery, which encourages the widespread use of these procedures. A number of significant firms are investing in R&D to bring cutting-edge minimally invasive surgical devices to uterine fibroid treatment devices market.

One of the incision techniques that is highly suggested by doctors is the MR-guided Focused Ultrasound (MRgFUS) used to treat uterine fibroids. Targeted tissue from the uterine cavity is heated and removed during this treatment by the device's ultrasonic beams. Since it is a non-invasive procedure, there are little to no side effects, and patients can resume their regular activities in a few days. Thus, it is projected that the demand for uterine fibroid treatment devices market would increase due to the increased demand for such operations due to their minimum pain, effectiveness, reduced risk of infection, and quick recovery as compared to open surgeries.

Therapeutic Landscape of Uterine Fibroid Treatment Devices Market

For the treatment of uterine fibroids, various options are available. While non-invasive or semi-invasive methods try to alleviate symptoms and eventually shrink the fibroids, medical therapy targets symptom relief.

The womb is surgically removed during a hysterectomy. It is the best method for preventing the recurrence of fibroids. If the patient doesn’t want to have any more children and has huge fibroids or significant bleeding, a hysterectomy may be advised.

A hysterectomy can be performed in a variety of ways, including through the vagina or through numerous tiny cuts (incisions) in the abdomen. Hysterectomy procedures can be done under spinal or epidural anesthesia, which numbs the lower body, depending on the technique.

A myomectomy is a surgical procedure to remove fibroids from the uterine wall. If the patient still wants to have children, it might be taken into consideration as an alternative to a hysterectomy. But not all fibroid types respond well to a myomectomy.

Depending on the size and location of the fibroids, a myomectomy may need several tiny incisions (keyhole surgery) or one larger incision in your abdomen (open surgery).

During a hysteroscopic excision of fibroids, fibroids are removed using a thin telescope (hysteroscope) and tiny surgical instruments. Submucosal fibroids can be removed using this method, which is acceptable for women who intend to have children in the future.

Hysteroscopes can be put through the vagina and into the womb through the womb entrance without making any incisions (cervix). To ensure the removal of as much fibroid tissue as feasible, several insertions are required.

The two surgical procedures that are used most frequently to treat uterine fibroids are hysterectomy and myomectomy. The uterus (and typically the cervix) is removed during a hysterectomy, either with or without ovarian preservation. Individual fibroids are removed during a myomectomy, leaving the uterus and the possibility of pregnancy intact.

Emerging Techniques and Devices in the Uterine Fibroid Treatment Devices Market

Regarding the most promising treatment, Ulipristal (UPA), the effects of the introduction of this novel class of compounds for the medical management of fibroids have been examined by numerous organisations. It has been specifically noted that a number of criteria, such as the intensity of symptoms, the characteristics of myomas, age, and a desire to retain fertility, influence the selection of a given treatment.

Alternatives to surgical intervention are needed in this situation, and today, selective progesterone receptor modulator (SPRM) is one such option. Two recent reviews examined the role of SPRM in the long-term medical management of hormone-dependent conditions like uterine fibroids, and they concluded that this class of compounds has emerged as an important alternative capable of providing women with effective long-term medical management and avoiding surgery entirely.

For symptomatic uterine fibroids, the Sonata® system offers transcervical fibroid therapy (TFA). It is a radiofrequency ablation procedure that is approved and marketed in both Europe and the United States. It is sonography-guided, non-invasive, and preserves the uterus. Sonata is a therapeutic method that combines a single-use radiofrequency ablation handpiece with a reusable intrauterine ultrasonography probe to remove uterine fibroids.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the uterine fibroid treatment devices market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. Techniques like the development of instruments that can safely apply radio frequency energy to destroy fibroids have opened up a whole new world of minimally invasive possibilities for people who want to save their uterus. The companies included in this market are as follows:

• Medtronic

• Boston Scientific Corporation

• Cooper Surgical Inc.

• Stryker Corporation

• Minerva Surgical, Inc.

• AbbVie, Inc.

• Ethicon, Inc.

• Lumenis Ltd

• Smith & Nephew PLC

• Merit Medical Systems, Inc.

• Hologic, Inc.

• ConMed Corporation

• Gynesonics, Inc.

Key Highlights of the Report